Abstract

Introduction: Excess weight, insulin, insulin resistance and IGF-1 have been associated with breast cancer prognosis, but less is known about the association between these factors and Ki67 index, a marker of cell proliferation in malignant breast tumors. Methods: Women with newly diagnosed stage III invasive breast cancer, aged 35-75 years, were invited to participate in a small clinical study, in order to study whether insulin, IGF-1 and insulin resistance [Homeostasis Model Assessment (HOMA)-score], were associated with Ki-67 index, a marker of cell proliferation in malignant breast tumors. Before surgery, body mass index [BMI, kg/m], waist circumference [cm], and total and truncal fat percentage [dual-emission X-ray absorptiometry], and fasting serum concentrations of insulin, IGF-1 and insulin resistance were assessed and determined. Ki67 index was determined as the percentage of Ki67-positive tumor cells according to national and international guidelines. Linear regression models were used to test for associations between Ki67 and selected patient characteristics. Results: Among these 45 breast cancer patients included, mean age at diagnosis was 54.9 years, BMI was 24.8 kg/m and mean waist circumference was 87.0 cm. Altogether, 91.1% of patients had estrogen receptor (ER)-positive tumors (> 1 % ER+), and 28.9% had axillary lymph node metastases. There was a negative association between Ki67 index and age (p=0.012), ER-positive tumors (p<0.0001), and progesterone receptor (PR)-positive tumors (p=0.001), and a positive association between Ki67 and histologic grade 3 versus 1 (p <0.0001). Among premenopausal patients, Ki67 was positively associated with insulin resistance, (p=0.097) and IGF-1 (p=0.025). Conclusion: Our results, although small number of patients included, hypothesize an association between IGF-1, insulin resistance and Ki67 index. Our results should be focused in larger studies in where more detailed subgroup analysis can be performed.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call